Subtype
Pilocytic Astrocytoma
CI-CAN-00008240Explore in graph →
Non-malignant5 active trials10 evidence items
Loading cancer entity…
Subtype
CI-CAN-00008240Explore in graph →
Clinical trials
21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01553149 | Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 4 | Jan 7, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2025source: clinicaltrials
| NCT02684058 |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors |
| completed |
| Phase 2 |
| 151 |
| Novartis PharmaceuticalsINDUSTRY |
| 20 |
| Dec 13, 2023 |
| clinicaltrials |
| NCT01119599 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00112736 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2015 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |